Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 554

1.

Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer.

Parimi S, Bondy S, Tsang E, McKenzie MR, Bachand F, Aparicio M, Duncan G, Sunderland K, Olson RA, Pai HH, Alexander AS, LaPointe V, Chi KN, Tyldesley S.

Can Urol Assoc J. 2019 Feb 7. doi: 10.5489/cuaj.5685. [Epub ahead of print]

PMID:
31364977
2.

2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC).

Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North S, Pouliot F, Rendon R, Shayegan B, Sridhar S, So A, Usmani N, Vigneault E, Chi KN.

Can Urol Assoc J. 2019 Jun 25. doi: 10.5489/cuaj.6136. [Epub ahead of print] No abstract available.

PMID:
31348741
3.

Human action recognition based on HOIRM feature fusion and AP clustering BOW.

Huan RH, Xie CJ, Guo F, Chi KK, Mao KJ, Li YL, Pan Y.

PLoS One. 2019 Jul 25;14(7):e0219910. doi: 10.1371/journal.pone.0219910. eCollection 2019.

4.

Knockdown of TM9SF4 boosts ER stress to trigger cell death of chemoresistant breast cancer cells.

Zhu Y, Xie M, Meng Z, Leung LK, Chan FL, Hu X, Chi K, Liu C, Yao X.

Oncogene. 2019 Jul;38(29):5778-5791. doi: 10.1038/s41388-019-0846-y. Epub 2019 Jun 27.

PMID:
31249383
5.

Correction to: Cellular distribution of cadmium in two amaranth (Amaranthus mangostanus L.) cultivars differing in cadmium accumulation.

Chi K, Zou R, Wang L, Huo W, Fan H.

Environ Sci Pollut Res Int. 2019 Aug;26(22):22159. doi: 10.1007/s11356-019-05618-9.

PMID:
31183752
7.

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.

PMID:
31157964
8.

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators.

N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31.

PMID:
31150574
9.

Minimization of Wound With the Assistance of a Needle Grasper in Single-Incision Laparoscopic Appendectomy.

Kim BJ, Kim JW, Choi YS, Park YG, Kim BG, Park JM, Lee SE, Park BK, Suh SW, Chi KC.

Surg Innov. 2019 May 27:1553350619848555. doi: 10.1177/1553350619848555. [Epub ahead of print]

PMID:
31132924
10.

Selective and quantitative synthesis of a linear [3]catenane by two component coordination-driven self-assembly.

Singh J, Kim DH, Kim EH, Singh N, Kim H, Hadiputra R, Jung J, Chi KW.

Chem Commun (Camb). 2019 Jun 11;55(48):6866-6869. doi: 10.1039/c9cc03336j.

PMID:
31124548
11.

Cellular distribution of cadmium in two amaranth (Amaranthus mangostanus L.) cultivars differing in cadmium accumulation.

Chi K, Zou R, Wang L, Huo W, Fan H.

Environ Sci Pollut Res Int. 2019 Aug;26(22):22147-22158. doi: 10.1007/s11356-019-05390-w. Epub 2019 May 21. Erratum in: Environ Sci Pollut Res Int. 2019 Jun 10;:.

PMID:
31115806
12.

Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer.

Sumanasuriya S, Omlin A, Armstrong A, Attard G, Chi KN, Bevan CL, Shibakawa A, IJzerman MJ, De Laere B, Lolkema M, Lorente D, Luo J, Mehra N, Olmos D, Scher H, Soule H, Stoecklein NH, Terstappen LWMM, Waugh D, de Bono JS.

Eur Urol Oncol. 2018 Jun;1(2):151-159. doi: 10.1016/j.euo.2018.02.009. Epub 2018 May 15. Review.

13.

Chronic immune barrier dysregulation among women with a history of violence victimization.

Swaims-Kohlmeier A, Haddad LB, Li ZT, Brookmeyer KA, Baker JM, Widom CS, Lamousin JC, Chi KH, Chen CY, Kersh EN, Johnson JA, Herbst-Kralovetz MM, Hogben M, Ofotokun I, Kohlmeier JE.

JCI Insight. 2019 May 16;4(10). pii: 126097. doi: 10.1172/jci.insight.126097. eCollection 2019 May 16.

14.

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205.

Hotte SJ, Chi KN, Joshua AM, Tu D, Macfarlane RJ, Gregg RW, Ruether JD, Basappa NS, Finch D, Salim M, Winquist EW, Torri V, North S, Kollmannsberger C, Ellard SL, Eigl BJ, Tinker A, Allan AL, Beja K, Annala M, Powers J, Wyatt AW, Seymour L; Canadian Cancer Trials Group (formerly NCIC Clinical Trials Group).

Clin Genitourin Cancer. 2019 Jun;17(3):201-208.e1. doi: 10.1016/j.clgc.2019.03.005. Epub 2019 Mar 15.

PMID:
31056399
15.

Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis.

Tsang ES, Forbes C, Chi KN, Eigl BJ, Parimi S.

Curr Oncol. 2019 Apr;26(2):e260-e265. doi: 10.3747/co.26.4070. Epub 2019 Apr 1.

16.

Management algorithms for metastatic prostate cancer.

Malone S, Shayegan B, Basappa NS, Chi K, Conter HJ, Hamilton RJ, Hotte SJ, Saad F, So A, Park-Wyllie L, Hew H, McLeod D, Gotto G.

Can Urol Assoc J. 2019 Apr 26. doi: 10.5489/cuaj.5840. [Epub ahead of print] Review.

PMID:
31039111
17.

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN.

Lancet Oncol. 2019 May;20(5):686-700. doi: 10.1016/S1470-2045(19)30082-8. Epub 2019 Apr 12.

PMID:
30987939
18.

A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer.

Rousseau E, Wilson D, Lacroix-Poisson F, Krauze A, Chi K, Gleave M, McKenzie M, Tyldesley S, Goldenberg SL, Bénard F.

J Nucl Med. 2019 Apr 12. pii: jnumed.119.226381. doi: 10.2967/jnumed.119.226381. [Epub ahead of print]

PMID:
30979820
19.

Paddlewheel SBU based Zn MOFs: Syntheses, Structural Diversity, and CO₂ Adsorption Properties.

Lin TR, Lee CH, Lan YC, Mendiratta S, Lai LL, Wu JY, Chi KM, Lu KL.

Polymers (Basel). 2018 Dec 17;10(12). pii: E1398. doi: 10.3390/polym10121398.

20.

Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.

Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ; West Coast Prostate Cancer Dream Team.

Eur Urol. 2019 Mar 27. pii: S0302-2838(19)30206-4. doi: 10.1016/j.eururo.2019.03.020. [Epub ahead of print]

PMID:
30928160
21.

Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.

Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ.

Mol Cancer Res. 2019 Jun;17(6):1235-1240. doi: 10.1158/1541-7786.MCR-18-1101. Epub 2019 Mar 27.

PMID:
30918106
22.

Energy Storage Overflow-Aware Data Delivery Scheme for Energy Harvesting Wireless Sensor Networks.

Lu W, Zhu YH, Chi K.

Sensors (Basel). 2019 Mar 20;19(6). pii: E1383. doi: 10.3390/s19061383.

23.

A case of inguinal lymphogranuloma venereum imitating malignancy on CT imaging.

Promer K, Pillay A, Chi KH, Vahdat N, Katz SS, Chen CY, Fierer J.

Radiol Case Rep. 2019 Mar 5;14(5):581-583. doi: 10.1016/j.radcr.2019.02.012. eCollection 2019 May.

24.

Modulated electro-hyperthermia-enhanced liposomal drug uptake by cancer cells.

Tsang YW, Chi KH, Huang CC, Chi MS, Chiang HC, Yang KL, Li WT, Wang YS.

Int J Nanomedicine. 2019 Feb 18;14:1269-1279. doi: 10.2147/IJN.S188791. eCollection 2019. Erratum in: Int J Nanomedicine. 2019 Mar 19;14:1995-1996.

25.

Measurement of PCNs in sediments collected from reservoir and river in northern Taiwan.

Dat ND, Chang KS, Wu CP, Chen YJ, Tsai CL, Chi KH, Chang MB.

Ecotoxicol Environ Saf. 2019 Jun 15;174:384-389. doi: 10.1016/j.ecoenv.2019.02.087. Epub 2019 Mar 5.

PMID:
30849659
26.

A study on spleen transient elastography in predicting the degree of esophageal varices and bleeding.

Wang XK, Wang P, Zhang Y, Qi SL, Chi K, Wang GC.

Medicine (Baltimore). 2019 Mar;98(9):e14615. doi: 10.1097/MD.0000000000014615.

27.

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.

Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB.

Prostate Cancer Prostatic Dis. 2019 Feb 25. doi: 10.1038/s41391-019-0134-5. [Epub ahead of print]

PMID:
30804427
28.

Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies.

Lin YL, Tsai NM, Chen CH, Liu YK, Lee CJ, Chan YL, Wang YS, Chang YC, Lin CH, Huang TH, Wang CC, Chi KH, Liao KW.

J Nanobiotechnology. 2019 Feb 6;17(1):25. doi: 10.1186/s12951-019-0457-3.

29.

2D-porphrinic covalent organic framework-based aptasensor with enhanced photoelectrochemical response for the detection of C-reactive protein.

Zhang X, Chi KN, Li DL, Deng Y, Ma YC, Xu QQ, Hu R, Yang YH.

Biosens Bioelectron. 2019 Mar 15;129:64-71. doi: 10.1016/j.bios.2019.01.009. Epub 2019 Jan 15.

PMID:
30684856
30.

Emulsions prepared by ultrahigh methoxylated pectin through the phase inversion method.

Hua X, Ding P, Wang M, Chi K, Yang R, Cao Y.

Int J Biol Macromol. 2019 May 1;128:167-175. doi: 10.1016/j.ijbiomac.2019.01.111. Epub 2019 Jan 23.

PMID:
30682476
31.

New Self-assembled Supramolecular Bowls as Potent Anticancer Agents for Human Hepatocellular Carcinoma.

Song HS, Song YH, Singh N, Kim H, Jeon H, Kim I, Kang SC, Chi KW.

Sci Rep. 2019 Jan 18;9(1):242. doi: 10.1038/s41598-018-36755-9.

32.

A Population-Based Study of Palliative Radiation Therapy for Bone Metastases in Patients Dying of Prostate Cancer.

Cho CJ, Sunderland K, Pickles T, Bachand F, Chi KN, Tyldesley S.

Pract Radiat Oncol. 2019 May;9(3):e274-e282. doi: 10.1016/j.prro.2019.01.002. Epub 2019 Jan 11.

PMID:
30641243
33.

Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.

Vandekerkhove G, Struss WJ, Annala M, Kallio HML, Khalaf D, Warner EW, Herberts C, Ritch E, Beja K, Loktionova Y, Hurtado-Coll A, Fazli L, So A, Black PC, Nykter M, Tammela T, Chi KN, Gleave ME, Wyatt AW.

Eur Urol. 2019 Apr;75(4):667-675. doi: 10.1016/j.eururo.2018.12.042. Epub 2019 Jan 10.

PMID:
30638634
34.

Evaluation of the Biological Behavior of a Gold Nanocore-Encapsulated Human Serum Albumin Nanoparticle (Au@HSANP) in a CT-26 Tumor/Ascites Mouse Model after Intravenous/Intraperitoneal Administration.

Chen CC, Li JJ, Guo NH, Chang DY, Wang CY, Chen JT, Lin WJ, Chi KH, Lee YJ, Liu RS, Chen CL, Wang HE.

Int J Mol Sci. 2019 Jan 8;20(1). pii: E217. doi: 10.3390/ijms20010217.

35.

Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.

Khalaf DJ, Sunderland K, Eigl BJ, Kollmannsberger CK, Ivanov N, Finch DL, Oja C, Vergidis J, Zulfiqar M, Gleave ME, Chi KN.

Eur Urol. 2019 Jun;75(6):940-947. doi: 10.1016/j.eururo.2018.12.015. Epub 2018 Dec 24.

PMID:
30591354
36.

Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.

Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM Jr, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small EJ, Kelly WK.

J Clin Oncol. 2019 Feb 10;37(5):403-410. doi: 10.1200/JCO.18.01279. Epub 2018 Dec 21.

PMID:
30576268
37.

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.

Basch EM, Scholz M, de Bono JS, Vogelzang N, de Souza P, Marx G, Vaishampayan U, George S, Schwarz JK, Antonarakis ES, O'Sullivan JM, Kalebasty AR, Chi KN, Dreicer R, Hutson TE, Dueck AC, Bennett AV, Dayan E, Mangeshkar M, Holland J, Weitzman AL, Scher HI.

Eur Urol. 2019 Jun;75(6):929-937. doi: 10.1016/j.eururo.2018.11.033. Epub 2018 Dec 4.

38.

Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: Results from LATITUDE.

Li T, Franco-Villalobos C, Proskorovsky I, Sorensen SV, Tran N, Sulur G, Chi KN.

Cancer. 2019 Feb 15;125(4):626-632. doi: 10.1002/cncr.31847. Epub 2018 Dec 6.

PMID:
30521063
39.

Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.

Mahon KL, Qu W, Lin HM, Spielman C, Cain D, Jacobs C, Stockler MR, Higano CS, de Bono JS, Chi KN, Clark SJ, Horvath LG.

Eur Urol. 2019 Sep;76(3):306-312. doi: 10.1016/j.eururo.2018.11.001. Epub 2018 Nov 19.

PMID:
30466891
40.

Promoted Glycerol Oxidation Reaction in an Interface-Confined Hierarchically Structured Catalyst.

Chen Z, Liu C, Zhao X, Yan H, Li J, Lyu P, Du Y, Xi S, Chi K, Chi X, Xu H, Li X, Fu W, Leng K, Pennycook SJ, Wang S, Loh KP.

Adv Mater. 2019 Jan;31(2):e1804763. doi: 10.1002/adma.201804763. Epub 2018 Nov 9.

PMID:
30412314
41.

Mid-term Results of a Novel Dedicated Venous Stent for the Treatment of Chronic Thoracic Central Vein Obstruction of Benign Aetiology.

Tan GM, Chi KWK, Yan BPY.

Eur J Vasc Endovasc Surg. 2019 Mar;57(3):417-423. doi: 10.1016/j.ejvs.2018.10.009. Epub 2018 Nov 4.

PMID:
30404722
42.

Arginine starvation kills tumor cells through aspartate exhaustion and mitochondrial dysfunction.

Cheng CT, Qi Y, Wang YC, Chi KK, Chung Y, Ouyang C, Chen YR, Oh ME, Sheng X, Tang Y, Liu YR, Lin HH, Kuo CY, Schones D, Vidal CM, Chu JC, Wang HJ, Chen YH, Miller KM, Chu P, Yen Y, Jiang L, Kung HJ, Ann DK.

Commun Biol. 2018 Oct 26;1:178. doi: 10.1038/s42003-018-0178-4. eCollection 2018.

43.

Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.

Lavoie JM, Zou K, Khalaf D, Eigl BJ, Kollmannsberger CK, Vergidis J, Noonan K, Zulfiqar M, Finch D, Chi KN.

Prostate. 2019 Feb;79(3):281-287. doi: 10.1002/pros.23733. Epub 2018 Oct 28.

PMID:
30370697
44.

Increased Discrimination of Treponema pallidum Strains by Subtyping With a 4-Component System Incorporating a Mononucleotide Tandem Repeat in rpsA.

Pillay A, Lee MK, Slezak T, Katz SS, Sun Y, Chi KH, Morshed M, Philip S, Ballard RC, Chen CY.

Sex Transm Dis. 2019 Apr;46(4):e42-e45. doi: 10.1097/OLQ.0000000000000935.

PMID:
30365462
45.

An Adult Drosophila Glioma Model for Studying Pathometabolic Pathways of Gliomagenesis.

Chi KC, Tsai WC, Wu CL, Lin TY, Hueng DY.

Mol Neurobiol. 2019 Jun;56(6):4589-4599. doi: 10.1007/s12035-018-1392-2. Epub 2018 Oct 24.

PMID:
30357574
46.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. No abstract available.

47.

Developing prognostic models for advanced prostate cancer when the goal line keeps changing.

Fu SYF, Chi KN.

Ann Oncol. 2018 Nov 1;29(11):2155-2157. doi: 10.1093/annonc/mdy419. No abstract available.

PMID:
30307525
48.

DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.

Warner EW, Yip SM, Chi KN, Wyatt AW.

BJU Int. 2019 May;123(5):769-776. doi: 10.1111/bju.14576. Epub 2018 Oct 26. Review.

PMID:
30281887
49.

Frequent mutation of the FOXA1 untranslated region in prostate cancer.

Annala M, Taavitsainen S, Vandekerkhove G, Bacon JVW, Beja K, Chi KN, Nykter M, Wyatt AW.

Commun Biol. 2018 Aug 24;1:122. doi: 10.1038/s42003-018-0128-1. eCollection 2018.

50.

Molecular strain typing of the yaws pathogen, Treponema pallidum subspecies pertenue.

Katz SS, Chi KH, Nachamkin E, Danavall D, Taleo F, Kool JL, Addo KK, Ampofo W, Simpson SV, Ye T, Asiedu KB, Ballard RC, Chen CY, Pillay A.

PLoS One. 2018 Sep 12;13(9):e0203632. doi: 10.1371/journal.pone.0203632. eCollection 2018.

Supplemental Content

Support Center